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Abstract
Background—Members of the genus Echinacea are used medicinally to treat upper respiratory
infections such as colds and influenza. The aim of the present investigation was to characterize the
phytomedicinal properties of the American federally endangered species Echinacea tennesseensis.
Methods—Fifty-percent ethanol tinctures were prepared from roots, stems, leaves, and flowers and
tested separately for their ability to influence production of IL-1β, IL-2, IL-10, and TNF-α as well
as proliferation by young human adult peripheral blood mononuclear cells (PMBC) in vitro. Tincture
aliquots were stored at three different temperatures (4°, −20°C, and −80°C) for 21 h before testing.
At one-month post-extraction, tinctures stored at −20°C were tested again for cytokine modulation.
Phytochemical analyses were performed using HPLC.
Results—Fresh root, leaf, and flower tinctures stimulated PBMC proliferation. Fresh root tinctures
alone stimulated IL-1β, IL-10, and TNF-α production. No tinctures modulated IL-2 production. Stem
tinctures showed no activity. Storage temperature did not influence any outcomes. Root tinctures
maintained their ability to modulate IL-1β, IL-10, and TNF-α production after one month of storage
at −20°C.
Conclusions—These results suggest E. tennesseensis harbors phytomedicinal properties that vary
by plant organ, with roots demonstrating the strongest activities.
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1. Introduction
Alternative medical therapies, including herbal preparations such as those from Echinacea
spp., are gaining use in the United States [1,2]. The genus Echinacea is used most frequently
for preventing or treating upper respiratory infections such as colds and influenza [3,4];
however, while some studies have supported its use in this capacity [5–8], others have
suggested it may be ineffective [9–12]. Since Echinacea angustifolia, E. pallida, and E.
purpurea are used commercially, these three species have received the overwhelming majority
of scientific attention and much data exists regarding their genetics, phytochemistry,
immunomodulatory activity, and efficacy in clinical settings [13]. By comparison, very little
is known about the American federally endangered species E. tennesseensis.
Several classes of purported medicinal compounds have been identified from this genus, but
current data suggest that no single molecule or class of molecules is responsible for
Echinacea’s activities [13]. Known bioactive molecules include alkamides, caffeic acid
derivatives, and polysaccharides. Present bioavailability studies suggest that alkamides most
likely account for the majority of observed immunomodulatory effects [14,15].
Much of the published work has focused on the phytochemistry of Echinacea tennesseensis.
Three diacetylenic isobutylamides (polyacetylenes) have been identified from E.
tennesseensis seedlings; further, in a cross-genus comparison it was shown that E.
tennesseensis harbors higher levels of one of these compounds (amide 5) as compared to other
members of the genus [16]. In contrast, other bioactive molecules such as phenolic compounds
(including caffeic acid derivatives) were found to be lower in E. tennesseensis root extracts
than in extracts from other sister species [17]. Levels of alkenes, amides, and caffeic acid
derivatives from E. tennesseensis root extracts in comparison to sister species have been
reported [18]. In particular, this species harbors higher levels of several monoene and tetraene
amides (phytochemicals with demonstrated antiviral activity [18]), but perhaps lower levels
of caffeic acids and their derivatives, compared to other Echinacea species.
Previously, our lab reported that E. tennesseensis root extracts may harbor immunomodulatory
properties, based on multiple studies from two different extracts sets. For the first extract set,
we used freshly-harvested late autumn root material which was diced and then extracted at a
ratio of 1:9 parts plant:solvent for 1 h in either 50% ethanol/50% sterile water (tincture), or hot
or cold sterile water (infusions) [19]. We found that the ethanol tincture from this species had
the capacity to enhance TNF-α production while suppressing IL-12 production by human
peripheral blood mononuclear cells (PBMCs) cultured in vitro [19]. We also showed that the
ethanol tinctures were more active than cold or hot water infusions made from the same plant
stock [19]. In a follow-up investigation, identical aliquots that had been stored undisturbed at
−20°C for 2 years were tested in the same assays [20]. This particular storage regimen was
found to alter the immunomodulatory properties of E. tennesseensis extract such that it no
longer had any impact on TNF-αor IL-12 production, yet instead acquired the ability to
stimulate IL-10 production and PBMC proliferation [20]. When the frozen extracts were co-
cultured with influenza virus using PBMCs isolated from individuals vaccinated against those
same virus strains, extracts from E. tennesseensis did not modulate IL-2, IL-10, or IFN-γ
[20]. For the second extract set, we used late autumn root material which was dried in a climate-
controlled facility for 16 months prior to being diced and then extracted at the same ratio but
for only 20 minutes [21]. In the context of influenza virus-stimulated PBMCs from older
individuals vaccinated against influenza, we showed that E. tennesseensis root tinctures
augmented IL-10 production, diminished IL-2 production, and had no effect on IFN-γ
production [21]. When the same extract was tested alone using PBMCs from unvaccinated
individuals, it was able to augment IL-1β and TNF-α, but not IL-2, production [22]. Only root
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extracts were used in these studies, so at present, the immunomodulatory properties of extracts
from other E. tennesseensis tissues are unclear.
The aim of the present work was to more fully characterize the immunomodulatory properties
of E. tennesseensis. To achieve this aim, we prepared ethanol tinctures from roots, stems,
leaves, and flowers separately and tested their abilities to modulate PBMC production of
IL-1β, IL-2, IL-10, and TNF-α, as well as PBMC proliferation. We also investigated whether
storage temperature conditions influenced outcomes.
2. Methods
2.1 Plant selection and extraction
A lone individual of Echinacea tennesseensis (PI631250) was harvested from a field population
at the North Central Regional Plant Introduction Station in Ames, Iowa on June 21, 2005. The
plant was processed into extracts less than 3 h after harvesting.
The plant was rinsed with Nanopure water. Roots, stems, leaves, and flowering tops were
separately minced with a surgical scalpel and dissolved in 50% ethanol and 50% sterile water
at a ratio of 1 part plant, 4 parts solvent to generate ethanol tinctures. Preparations steeped at
room temperature for 1 h on a horizontal agitator before being filtered through sterilized tulle.
Tinctures were fractionated into three aliquots for storage at 4°C, −20°C, and −80°C. To mimic
the freeze/thaw cycles that laboratory extracts typically experience as a result of repeated
handling for separate experiments, all aliquots were removed and brought to room temperature
every 7 h for 21 h (total 3 cycles). Following initial testing of the fresh extracts, the −20°C
aliquots were saved and tested again 1 month later. We chose the aliquots stored at this
temperature because this is the typical storage temperature used in many laboratories. Extracts
will be referred to as “Day 1” or “Day 31” in this report.
2.2 Phytochemical profiling
Phytochemical analysis was performed to detect alkamides and caffeic acid derivatives in the
Echinacea extracts with the use of high performance liquid chromatography (HPLC). We have
previously published a supplement showing the full names and chemical structures of these
compounds (PDF freely downloadable from
http://www.thieme-connect.com/bilder/planta/200613/supmat/324sup_10-1055-
s-2006-947254.pdf) except for amides 16 and 17 which are undeca-2Z-ene-8,10-diynoic acid
2-methylbutylamide and dodeca-2E-ene-8,10-diynoic acid 2-methylbutylamide, respectively
[23]. Before analysis, into 160 μl of Echinacea extracts, 15 μl (1 mg ml−1) N-isobutylundeca-2-
ene-8,10-diynamide (C15H21O2) and 15 μl (1 mg ml−1) 3,5-dimethoxy-4-hydroxy-cinnamic
acid (C11H12O5) were added as internal standards for quantification of lipophilic metabolites
and hydrophilic metabolites, respectively. Fifteen microliters of each sample were injected into
a Beckman Coulter HPLC with a 508 autosampler, 126 pump control and 168 UV-photodiode
array detector controlled by 32karat ™ software (Version 5.0), and a YMC-Pack ODS-AM RP
C18 (250 × 4.6 mm, 5 μm) analytical column (Waters, MA). The solvent system for lipophilic
constituents was acetonitrile/H2O at a flow rate of 1.0 ml/min following a linear gradient of
40–80% acetonitrile over 45 min. The solvent system for hydrophilic constituents consisted
of acetonitrile/H2O and 0.01% formic acid, at a flow rate of 1.0ml/min following a linear
gradient of 10–35% acetonitrile over 25 min. Online UV spectra were collected between 190–
400 nm.
For compound identification, alkamides 8/9, cichoric acid, echinacoside, caftaric acid were
purchased from Phytolab, Germany; chlorogenic acid was purchased from Sigma Aldrich,
USA; alkamides 8, 10, 11, 12, 13, and 14 were synthesized by Dr. George Kraus, Department
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of Chemistry, Iowa State University [16,24]. In the absence of standards, alkamides 1, 16, and
17 were identified by HPLC fractionation coupled with GC-MS analysis. Phytochemicals were
quantified based on the internal standard with the limit of HPLC detection at approximately
0.02 μg/ml.
2.3 Human subjects and cell culture
All procedures involving human subjects were approved by the Institutional Review Board of
Iowa State University. Sixteen subjects between the ages of 19–36 donated blood for the testing
of the fresh extracts. Four of these same subjects donated blood for the testing of the one-
month-old extracts. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-
Paque plus (Amersham Pharmacopia Biotech, Piscataway, NJ) gradient centrifugation. Cell
counts were performed with a hemacytometer using Trypan Blue to assess viability; all cell
suspensions were adjusted to 1.0 × 106 cells/mL in AIM-V media (GIBCO/Invitrogen,
Carlsbad, CA).
For the cytokine assays, one milliliter of AIM-V media containing cells (1.0 × 106 cells) was
plated per well in 24-well Costar tissue culture plates. Fifty microliters of one of the
Echinacea preparations diluted 1:12.5 was added per treatment well; the control well received
50 microliters of AIM-V media. This extract concentration was determined from preliminary
studies of human PBMC ethanol tolerability (data not shown). Cell cultures were incubated
for 24 h at 37°C, 5.0% carbon dioxide in a humidified atmosphere. Supernatants were harvested
and stored at −20°C until used in cytokine quantification assays for IL-1β, IL-2, IL-10, and
TNF-α via ELISA (BD Biosciences Pharmingen, San Diego, CA). Due to experimental
complications during testing of the fresh extracts, our sample size for IL-2 was n=14 and for
IL-10 n=8.
For the proliferation assay, one hundred microliters of AIM-V media containing 1.0 × 106 cells
were plated per well in 96-well flat-bottom Costar plates. Cells were stimulated with 5
microliters of Echinacea preparations diluted as above or AIM-V media (control). All trials
were conducted in triplicate. Cells were incubated for 5 d at 37° C, 5.0% carbon dioxide in a
humidified atmosphere and proliferation assessed via CellTiter (Promega, Madison, WI) per
manufacturer’s instructions and read in a plate reader (Bio-Rad, Hercules, CA).
All glassware used in the extract preparation was baked at 180°C for 16 h prior to use to
minimize endotoxin contamination. Sterile water was obtained from Hospira, Inc., Lake Forest,
IL and used for all tinctures. Endotoxin levels were determined from both sterile water (0 EU/
mL) and all stock tinctures using Bio-Whitaker QCL 1000 kits (Cambridge, MA).
A univariate ANOVA was used to test for significant differences in immune effects by plant
organ, storage temperature, and plant organ × storage temperature interactions for each
cytokine or measure of proliferation using SPSS 15.0 (Chicago, IL). “Plant organ” and “storage
temperature” were chosen as between-subjects factors and each immune outcome was chosen
as a dependent factor. Whenever significant effects were revealed, pairwise comparisons were
conducted to examine effects of individual extracts. An α level of 0.05 was used in all instances
as a threshold for statistical significance, whereas 0.10 was used as a threshold for statistical
trends.
3. Results
Endotoxin levels from all stock extracts were determined and are as follows (in EU/mL): root
(23.611), stem (1.252), leaf (1.464), flower (9.708). As described in Methods, the extracts were
diluted before being added to the wells. Thus, final endotoxin concentrations (EU/mL) in the
cell culture wells were: root (0.086), stem (0.005), leaf (0.005), flower (0.035). We have
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demonstrated elsewhere experimentally that these endotoxin levels are not likely to contribute
to immune outcomes in our assays [21]; therefore, we may gauge that the effects observed in
our assays are due to the Echinacea extracts themselves and not any contaminating endotoxin.
The phytochemical analysis of our extracts for alkamides and caffeic acid derivatives is
presented in Table 1. Although tested for, none of the caffeic acid derivatives (caffeic acid,
chlorogenic acid, cichoric acid, echinacoside) were detected in any of the samples. Root
contained all amides tested, whereas the other organs did not contain all of the amides. Root
showed the greatest whereas leaf showed the least diversity of amides. Quantities of each amide
differed by organ.
The abilities of the Day 1 extracts to stimulate cytokine production by peripheral blood
mononuclear cells (PBMCs) versus media alone (control) are shown in Figures 1–4. None of
the analyses produced significant main effects of storage temperature, nor any significant
organ-by-temperature interactions.
Results for IL-1β are shown in Fig. 1. A significant main effect of plant organ was found (p <
0.001). In pairwise comparisons, IL-1β production was found to be significantly enhanced by
root tinctures as compared to both control and all other tinctures (all p < 0.001). Although not
statistically significant, the root tincture stored at −80°C elicited approximately 1.3× as much
IL-1β as either of the root tinctures stored at 4°C or −20°C (−80°C = 11.67 ± 28.8 vs. 4°C =
84.2 ± 21.9 and −20°C = 85.9 ± 29.6). Storage temperature heterogeneously impacted on the
IL-1β-modulating abilities of extracts produced from other organs.
Results for IL-2 are shown in Fig. 2. A significant main effect of plant organ was found (p =
0.012). Pairwise comparisons indicated that none of the individual extracts significantly altered
IL-2 production as compared to control (all p ≥ 0.242). However, flower tinctures as a group
were significantly different from leaf (p = 0.002), root (p = 0.007), and stem (p = 0.051)
tinctures. No pattern could be discerned regarding storage temperature effects: for leaf and
flower extracts, colder storage temperatures resulted in extracts that stimulated greater IL-2
production, whereas for root extracts the pattern was opposite.
Results for IL-10 are shown in Fig. 3. A significant main effect of plant organ was found (p <
0.001). In pairwise comparisons, IL-10 production was found to be significantly enhanced by
root tinctures as compared to control (p = 0.001) and all other tinctures (all p < 0.001).
Generally, with the exception of the root extracts, warmer storage temperatures yielded extracts
that stimulated greater IL-10 production.
Results for TNF-α are shown in Fig. 4. A significant main effect of plant organ was found (p
< 0.001). Post-hoc analyses indicated that root tinctures significantly augmented TNF-α
production as compared to both control (p < 0.001) and all other tinctures (all p < 0.001).
Additionally, the flower tinctures showed a trend (p = 0.079) towards stimulating more TNF-
α production than the stem extract. Storage temperature heterogeneously impacted on the TNF-
α-modulating abilities of the extracts.
To examine possible effects of storage time, we re-tested the extracts stored at −20°C following
1 month of storage (Day 31), using the same experimental conditions as at Day 1. Extracts
were left undisturbed during the 1 month. Results from both Day 1 and Day 31 are displayed
in Table 2 (the data for Day 1 is a numerical expression of the same data found graphically in
Figs. 1–4, given again here for comparative purposes). For both IL-1β and TNF-αat Day 31,
a significant main effect of organ (both p ≤ 0.019) was found; post-hoc analyses indicated that
root tinctures alone significantly enhanced cytokine production as compared to control (both
p < 0.005) and all other tinctures (all p ≤ 0.007). For IL-10 at Day 31 there was a trend towards
a main effect of plant organ (p=0.086) such that the root tinctures significantly augmented
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IL-10 production as compared to both control (p = 0.02) and all other tinctures (all p ≤ 0.039).
No significant main effects were found for IL-2 at Day 31. When Day 1 and Day 31 data were
compared statistically, main effects of time (Day 1 vs. Day 31) were seen for IL-1β (p = 0.021)
such that Day 31 extracts elicited greater IL-1β production than Day 1 extracts, and for IL-2
(p < 0.001) such that Day 31 extracts elicited less IL-2 production than Day 1 extracts. Main
effects of time were not observed for TNF (p = 0.703) or IL-10 (p = 0.160) despite the
differences seen in Table 2.
The abilities of the 4°C Day 1 extracts to stimulate PBMC proliferation versus media alone
(control) are presented in Figure 5. A significant main effect of organ was found (p < 0.001).
Follow-up analyses indicated that the flower, leaf, and root tinctures were able to significantly
enhanced PBMC proliferation as compared to control (p < 0.001), whereas the stem tincture
did not (p = 0.237).
4. Discussion
Results from this study suggest that tinctures prepared from freshly harvested Echinacea
tennesseensis harbor phytomedicinal properties in vitro, but that these abilities vary by plant
organ. Production of the cytokines IL-1β, IL-10, and TNF-α were significantly enhanced by
E. tennesseensis root tinctures as compared to control, but not by flower, leaf, or stem tinctures
at both Days 1 and 31 (Figs. 1, 3, 4; Table 2). None of the tinctures modulated IL-2 production
at either time point (Fig. 2; Table 2). Considered together, these results suggest that E.
tennesseensis does harbor cytokine-modulating properties, but that these properties are more
pronounced in extracts generated from root tissues versus other organs.
Day 1 extracts stored at 4°C were also tested for their ability to modulate PBMC proliferation
(Fig. 5). Tinctures made from flower, leaf, and root were able to significantly enhance
proliferation (in contrast to what we observed with cytokine modulation), suggesting that all
organs except for stem harbor the phytochemicals or phytochemical combination responsible
for this property.
The immunomodulatory results presented here are congruent with findings published
previously from our laboratory. Generalizing from studies reviewed in the Introduction [19–
22], in in vitro studies using human PBMCs, E. tennesseensis root tincture has been reported
to increase IL-1β, decrease or have no effect on IL-2, increase or have no effect on IL-10,
increase or have no effect on TNF, and increase or have no effect on PBMC proliferation.
Comparisons between these studies should be made with the understanding that the studies
differed in extraction processes, laboratory culture procedures, participant characteristics, and
sample sizes. The extracts being investigated in this study differ from preceding batches in 2
major ways: (1) use of a 1:4 parts plant:solvent extraction ratio, and (2) use of material harvested
in the summertime. Despite these experimental design differences, the results from this paper
confirm and extend those of previous reports by demonstrating that E. tennesseensis root
tinctures, and root tinctures alone, produced via these methods are able to augment IL-1β, IL-10
and TNF-α (but not IL-2) production. Previously we found that E. tennesseensis root tinctures
did not significantly enhance PBMC proliferation [19], whereas in this study we report that
flower, leaf, and root tinctures harbor this ability. Differences in extraction procedure methods
most likely explain these differences. This is the first study to examine immunomodulatory
properties of stem, leaf, or flower tissues from E. tennesseensis.
Chemical analysis demonstrated that amide content differed between extracts made from
various organs of Echinacea tennesseensis (Table 1). Our research team has previously
reported a phytochemical analysis of Echinacea tennesseensis extracts generated during a prior
study [21]. Phytochemical results between this study and the previous study were quite
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different; as just one example, amides 1 and 8–11 were absent in our previous analysis, whereas
chlorogenic acid and echinacoside were present. Three main factors likely explain these
discrepancies, including the two enumerated in the preceding paragraph and also that, in the
aforementioned study [21], the E. tennesseensis specimen was dried for 16 months prior to
extraction, whereas in this study, the specimen was harvested and extracted within 3 h.
Interestingly, amides 14, 16, and 17 were present only in root extract, suggesting that these
phytochemicals may be partially responsible for the ability of root extract to modulate IL-1β,
IL-10 and TNF-α production. In contrast, amides 8, 9, and 12 were present in extracts from all
organs, suggesting that these phytochemicals may be partially responsible for the ability of all
extracts to modulate PBMC proliferation.
Our analyses indicated that there were no significant differences between the behaviors of
tinctures aliquoted from the same stock batch but stored at different temperatures for 21 h
before being tested for immunomodulatory properties. Previously, we investigated the effects
of 4 days storage at 4°C on the immunomodulatory properties of root infusions and tinctures
from several different Echinacea spp. to mimic the storage conditions that lay herbalists
typically employ [19]. We discovered that extract abilities changed over time, but this was
sometimes due to endotoxin effects. The results presented here suggest that laboratory
investigators wishing to study Echinacea extracts as lay herbalists produce them might be able
to store the extracts at freezing temperatures (i.e., −20°C, −80°C) for short-term purposes
without significantly altering their active properties as may be observed if they were stored at
4°C.
Results from Figs. 1–4 and Table 2 showed that a month of storage did not significantly alter
the cytokine-modulating properties of the tinctures tested in this investigation, at least in
statistical comparisons of extracts versus relevant controls. These results suggest that storage
of Echinacea tinctures for a short time period (one month) does not significantly change their
immunomodulatory behaviors from a statistical standpoint. However, storage time appeared
to increase the ability of the extracts to stimulate IL-10 production, and may have had
heterogeneous effects the ability of the extracts to influence TNF production.
The genus Echinacea is comprised of nine traditionally recognized species [25]. Of these nine,
only E. angustifolia, E. pallida, and E. purpurea are used to any appreciable extent in the herbal
supplement industry. Echinacea tennesseensis exhibits immunomodulatory properties similar
to some but not all other species of Echinacea. Other investigative teams as well as our own
have shown that E. angustifolia, E. pallida, and E. purpurea differ in both activity and/or
phytochemical composition [13,16–19,21,26–32]. In a previous phenetic analysis [22], we
established that Echinacea tennesseensis appears to exhibit in vitro immunomodulatory
characteristics more similar to E. purpurea than to E. angustifolia or E. pallida. Results
presented in this paper are consistent with previous findings and provide further support for
that analysis. The findings presented here, alongside previous antiviral [18], immune [19–
22], and phytochemical [16–18] data, suggest that E. tennesseensis may be of use in modern
herbalism.
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Figure 1.
Interleukin-1β production by human PBMC cultures stimulated with Echinacea
tennesseensis extracts. Bars represent means ± standard errors. Asterisks indicate statistical
significance compared to control (p ≤ 0.05).
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Figure 2.
Interleukin-2 production by human PBMC cultures stimulated with Echinacea tennesseensis
extracts. Bars represent means ± standard errors. Double asterisks indicate that flower extracts
as a group were significantly different than root, stem, or leaf extracts as groups (all p ≤ 0.051).
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Figure 3.
Interleukin-10 production by human PBMC cultures stimulated with Echinacea
tennesseensis extracts. Bars represent means ± standard errors. Asterisks indicate statistical
significance compared to control (p ≤ 0.05).
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Figure 4.
Tumor necrosis factor-α production by human PBMC cultures stimulated with Echinacea
tennesseensis extracts. Bars represent means ± standard errors. Asterisks indicate statistical
significance compared to control (p ≤ 0.05).
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Figure 5.
Proliferation of human PBMC stimulated with fresh Echinacea tennesseensis extracts. Bars
represent means ± standard errors. Asterisks indicate statistical significance compared to
control (p ≤ 0.05).
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Table 1
Phytochemical profiles of Echinacea tennesseensis extracts utilized in this investigation as determined by HPLC.
Values are mg/mL and represent means of three separate analyses of the same extract. ND = non-detectable.
Flower Leaf Stem Root
Amide 1 0.0056 ND ND 0.0066
Amide 8 0.0709 0.0068 0.0169 0.0117
Amide 9 0.1422 0.0041 0.0226 0.0058
Amide 10 0.0031 ND 0.0023 0.0074
Amide 11 0.0013 ND 0.0006 0.0041
Amide 12 0.0403 0.0009 0.0091 0.0907
Amide 13 ND ND 0.0008 0.3654
Amide 14 ND ND ND 0.0227
Amide 16 ND ND ND 0.0204
Amide 17 ND ND ND 0.0058
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